In a large real‐world cohort of premenopausal HR+/HER2+ breast cancer patients in the United States, the use of OS as part of adjuvant ET was uncommon and most women were prescribed tamoxifen alone as the preferred ET regimen regardless of several high risk clinicopathologic features. The gene discussed is ERBB2; the disease is breast cancer.